Karen Smith, M.D., Ph.D.

Karen Smith, M.D., Ph.D.

Former Chief Medical OfficeratIRulya Therapeutics· In proxies 2022–2023

Pay in FY2023-61% from the year before · IRulya Therapeutics stock +64.7% the same year

Karen Smith, M.D., Ph.D. was paid $1.3M in FY2023 (Dec), down 61%. IRulya Therapeutics stock rose 64.7% that year.

Pay$100 in the stock at the end of FY21 → $8
Pay is from the Summary Compensation Table of each IRulya Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. IRulya TherapeuticsPublic company · 4 yr
    • Former Chief Medical Officer2022 – Present · 4 yrStock in role -99%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?